<unk>  is approved for use concurrently with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or bilateral orchiectomy in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in men. It is used at a dosage of 600 mg orally twice per day (1,200 mg/day total) with food. In individuals with severe renal impairment or moderate hepatic impairment,<unk>  is used at a dosage of 300 mg orally twice per day (600 mg/day total) with food. No dosage adjustment is needed for mild to moderate renal impairment or mild hepatic impairment, whereas appropriate dosage adjustment for end-stage kidney disease and severe hepatic impairment is unknown. Two 2020 meta-analyses reported that enzalutamide and apalutamide seemed to be more effective than<unk>  in improving metastasis-free survival (MFS), however 2021 matched adjusted indirect comparison showed no significant differences between drugs in terms of MFS. According to 2021 meta-analysis<unk>  was ranked first in terms of improving overall survival (OS). Also,<unk>  showed significantly lower rate of grade 3-5 adverse events (AE) compared to both enzalutamide and apalutamide. Available forms<unk>  is provided in the form of 300 mg oral film-coated tablets.
Darolutamide
Bicalutamide
Acetothiolutamide
Apalutamide
Nilutamide
Topilutamide
Flutamide
Salvestrol